Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Ya-Ting Kuo, Wen-Sy Tsai, Hsin-Yuan Hung, Pao-Shiu Hsieh, Sum-Fu Chiang, Cheng-Chou Lai, Yih-Jong Chern, Yu-Jen Hsu, Jeng-Fu You
Summary: This study found that patients with LN+ metastatic colorectal cancer exhibit more high-risk pathological features, peritoneal seeding, and systemic node metastasis, leading to poorer long-term outcomes compared to LN- patients. However, with curative resection, LN+ patients could have similar survival outcomes as LN- patients.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Arndt Stahler, Volker Heinemann, Julian Walter Holch, Jobst Christian von Einem, Christoph Benedikt Westphalen, Kathrin Heinrich, Laura Schlieker, Ivan Jelas, Annabel Helga Sophie Alig, Laura Elisabeth Fischer, Lena Weiss, Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Markus Moehler, Florian Kaiser, Thomas Kirchner, Andreas Jung, Sebastian Stintzing
Summary: The study found that patients with mCRC who received cetuximab had higher objective response rate and overall survival. New mutations were observed in 18 patients after conversion therapy. Changes during cetuximab treatment were mainly gains, while losses were mainly observed during bevacizumab treatment.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B. Yurgelun, Douglas A. Rubinson, Deborah Schrag, Shaker R. Dakhil, Philip J. Stella, Douglas J. Weckstein, Donald B. Wender, Meredith Faggen, Tyler J. Zemla, Erica N. Heying, Samantha R. Schuetz, Stephanie Noble, Jeffrey A. Meyerhardt, Tanios Bekaii-Saab, Charles S. Fuchs, Kimmie Ng
Summary: The study investigated the efficacy of combining bevacizumab with irinotecan and cetuximab in patients with irinotecan-refractory metastatic colorectal cancer. Although there was no significant difference in progression-free survival between the two treatment groups, there was a statistically significant improvement in overall survival favoring the group that received bevacizumab in addition to irinotecan and cetuximab. Further investigation on this combination therapy is warranted.
Article
Biochemistry & Molecular Biology
Elena Elez, Javier Ros, Jose Fernandez, Guillermo Villacampa, Ana Belen Moreno-Cardenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Rossana Intini, Aldo Montagna, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo
Summary: In colorectal cancer patients, inactivating mutations in the RNF43 gene are associated with patients' response rates and survival outcomes to anti-BRAF/EGFR therapy. This suggests that the status of the RNF43 gene may serve as a predictive biomarker for patients' clinical outcomes.
Article
Pharmacology & Pharmacy
Changjing Cai, Qingqing Luo, Yihan Liu, Yinghui Peng, Xiangyang Zhang, Zhaohui Jiang, Ziyang Feng, Yaru Qi, Yan Gao, Yongting Liu, Ping Liu, Yihong Chen, Cao Guo, Hong Shen, Shan Zeng, Ying Han
Summary: This study conducted a comprehensive analysis of treatment regimens for left-sided RAS wild-type metastatic colorectal cancer (mCRC) and found that the double-drug regimen plus cetuximab/panitumumab was more effective and safer than the double-drug and triple-drug regimens with bevacizumab.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Yefei Shu, Ling Xu, Wei Yang, Xiaofeng Xu, Song Zheng
Summary: In patients with metastatic colorectal cancer, surgical resection of the primary tumor is associated with longer overall survival. However, for patients included in randomized controlled trials, there is no significant survival benefit from primary tumor resection.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Alexander J. Ohnmacht, Arndt Stahler, Sebastian Stintzing, Dominik P. Modest, Julian W. Holch, C. Benedikt Westphalen, Linus Hoelzel, Marisa K. Schuebel, Ana Galhoz, Ali Farnoud, Minhaz Ud-Dean, Ursula Vehling-Kaiser, Thomas Decker, Markus Moehler, Matthias Heinig, Volker Heinemann, Michael P. Menden
Summary: Precision medicine has revolutionized cancer treatments, but actionable biomarkers are still rare. In this study, the authors develop a framework called OncoBird to analyze the molecular and biomarker landscape of randomized controlled clinical trials, and apply it to a phase III trial investigating metastatic colorectal carcinoma patients.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Vanessa Wong, Margaret Lee, Rachel Wong, Jeanne Tie, Jeremy Shapiro, Jayesh Desai, Louise Nott, Simone Steel, Matthew Burge, Brigette Ma, Adnan Khattak, Wei Hong, Peter Gibbs
Summary: In metastatic colorectal cancer, left-side primary tumors with BRAF mutations share similar features with right-side primary tumors, including younger age and worse survival outcomes.
Article
Oncology
Yu-Wen Zhou, Yi-Xiu Long, Ye Chen, Ji-Yan Liu, Dan Pu, Jia-Yan Huang, Feng Bi, Qiu Li, Hong-Feng Gou, Meng Qiu
Summary: The study compared the efficacy of first-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy in metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. The results showed that bevacizumab-based chemotherapy was associated with significantly better overall survival in patients with mucinous adenocarcinoma or mucinous component, regardless of tumor sites.
Review
Pharmacology & Pharmacy
Zaina T. Al-Salama
Summary: Encorafenib in combination with cetuximab has shown significantly longer overall survival, higher response rate, and better tolerability in patients with mCRC and a BRAF V600E mutation who have had prior therapy.
Review
Oncology
Jan Zmuc, Jan Heil, Caroline Herfarth, Wolf O. Bechstein, Christine Koch, Joerg Trojan, Andreas A. Schnitzbauer
Summary: Chemotherapy with targeted therapy has improved overall response rate and survival in metastatic colorectal cancer patients. However, the resection rate has not seen the same improvement, mostly due to the lack of expert involvement.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Ozan Yazici, Gokhan Ucar, Osman Sutcuoglu, Nazim Serdar Turhal, Birol Yildiz, Michalis Karamouzis, Sinan Yavuz, Nuri Karadurmus, Nurullah Zengin, Ravit Geva, Huseyin Abali
Summary: This multinational registry study evaluated the real-life data on the survival of patients with metastatic colorectal cancer (mCRC). The study found that factors such as the patient's performance status, tumor location, and number of metastatic lesions at the time of diagnosis have an impact on the prognosis of mCRC.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)
Article
Oncology
Thierry Andre, Mayur Amonkar, Josephine M. Norquist, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J. A. Punt, Denis Smith, Rocio Garcia-Carbonero, Isabel Sevilla, Christelle de la Fouchardiere, Fernando Rivera, Elena Elez, Luis A. Diaz Jr, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Farooqui, Dung T. Le
Summary: The KEYNOTE-177 study found that pembrolizumab monotherapy significantly improved progression-free survival in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer compared to chemotherapy as first-line treatment, with clinically meaningful benefits. Health-related quality of life analyses further supported these findings.
Article
Medicine, General & Internal
Jun Watanabe, Kei Muro, Kohei Shitara, Kentaro Yamazaki, Manabu Shiozawa, Hisatsugu Ohori, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino
Summary: Adding panitumumab to standard first-line chemotherapy significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer, particularly in those with left-sided tumors.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Psychology, Developmental
Ying-Shan Chung, Shih-Chieh Shao, Mei-Hong Chi, Swu-Jane Lin, Chien-Chou Su, Yea-Huei Kao Yang, Yen-Kuang Yang, Edward Chia-Cheng Lai
Summary: A study compared the cardiometabolic risks of different antipsychotics in adolescents and young adults, finding a significant association between olanzapine and hypertension risk. The results suggest that clinicians should consider the various cardiometabolic risk profiles of antipsychotics when selecting treatment regimens.
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
(2021)
Letter
Gastroenterology & Hepatology
Yu-Xuan Wang, Min-Chi Chang, Chih-Chien Wu, Chu-Kuang Chou, Chiao-Hui Hsu, Chao-Wen Hsu
COLORECTAL DISEASE
(2021)
Article
Cardiac & Cardiovascular Systems
Po-Kai Yang, Chien-Chou Su, Chih-Hsin Hsu
Summary: Both surgical embolectomy and catheter-directed therapy show comparable outcomes in treating acute limb ischemia in Taiwan, with factors such as age, liver disease, heart failure, and chronic kidney disease affecting mortality and amputation risks for patients.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2022)
Article
Oncology
Chih-Chien Wu, Jui-Ho Wang, Min-Chi Chang, Yu-Hsun Chen, Yung-Chang Wang, Ming-Hung Lee, Chien-Yuan Lin, Yi-Chia Su, Pei-Chin Lin, Chao-Wen Hsu
Summary: The study found that patients, their families, and medical team members are most concerned about outcomes such as overall survival, progression-free survival, objective response rate, tumor shrinkage to resectable status, total medical cost, severe gastrointestinal perforation, and severe skin reaction. After a series of alpha tests for quality, quantitative evaluation, and beta tests, the average scores for both perceptibility and utility were more than 4 points on a scale of 1-5.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2022)
Article
Immunology
Ching-Fen Shen, Ju-Ling Chen, Chien-Chou Su, Wen-Liang Lin, Min-Ling Hsieh, Ching-Chun Liu, Ching-Lan Cheng
Summary: The implementation of PCV13 in Taiwan has significantly reduced hospitalizations for P-CAP, especially in children and adults, and has markedly decreased ICU rates and severe pneumonia cases.
Article
Medicine, General & Internal
Chih-Chien Wu, Chao-Wen Hsu, Meng-Che Hsieh, Jui-Ho Wang, Min-Chi Chang, Ching-Shiang Yang, Yi-Chia Su
Summary: The optimal sequence of treatment for patients with RAS wild-type metastatic colorectal cancer is not well established. Studies suggest that for second-line therapy, changing chemotherapy regimen with retention of bevacizumab may improve overall survival, while for patients treated with first-line CT plus anti-EGFR, second-line therapy of changed CT plus an anti-EGFR agent may result in better outcomes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Clinical Neurology
Cheng-Yang Hsieh, Chien-Chou Su, Edward Chia-Cheng Lai, Yu-Shiue Chen, Tzu-Hsin Huang, Yea-Huei Kao Yang, Chih-Hung Chen, Sheng-Feng Sung, Chin-Wei Huang
Summary: This study identified the conditions leading to a higher risk of poststroke epilepsy (PSE) and identified the important clinical risk factors in patients with middle cerebral artery (MCA) infarct.
FRONTIERS IN NEUROLOGY
(2022)
Article
Psychology, Developmental
Kenneth K. C. Man, Shih-Chieh Shao, Nathorn Chaiyakunapruk, Piyameth Dilokthornsakul, Kiyoshi Kubota, Junqing Li, Nobuhiro Ooba, Nicole Pratt, Anton Pottegard, Lotte Rasmussen, Elizabeth E. Roughead, Ju-Young Shin, Chien-Chou Su, Ian C. K. Wong, Yea-Huei Kao Yang, Edward Chia-Cheng Lai
Summary: Younger patients treated with antipsychotics face an increased risk of metabolic events. This study investigated how this risk varies according to ethnicity, the class of antipsychotic, and age group, and found that the risk is similar between Asian and non-Asian populations regardless of differences in drug utilization patterns.
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
(2022)
Article
Psychiatry
Kenneth K. C. Man, Shih-Chieh Shao, Yu-Chuan Chang, Mei-Hung Chi, Han Eol Jeong, Swu-Jane Lin, Chien-Chou Su, Ju-Young Shin, Kirstie H. Wong, Ian C. K. Wong, Yea-Huei Kao Yang, Yen-Kuang Yang, Edward Chia-Cheng Lai
Summary: The study found that long-term exposure to antipsychotics was associated with an increased risk of metabolic events but did not trigger cardiovascular events in children and young adults.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Chih-Chien Wu, Yi-Chia Su, Kuan-Sheng Wu, Tung-Ho Wu, Ching-Shiang Yang
Summary: The use of continuous/extended beta-lactam infusions (CEIs) with loading-dose treatment may significantly improve the clinical outcomes in critically ill sepsis or septic shock patients, according to a systematic review and meta-analysis.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2021)